Tin tức & Cập nhật

In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.

Treatment with monoclonal antibodies (mAbs) among COVID-19 patients is associated with a higher risk of hepatotoxicity and neutropenia when compared with standard of care (SoC) or placebo, reports a study.

In a large retrospective study, the incidence of bowel disorders and related procedures dropped when a polyethylene glycol-based hydrogel spacer (PHS) was used in men undergoing radiotherapy (RT) for prostate cancer.

First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.